TRIMTECH Therapeutics: Venture Capital Funding History
TRIMTECH Therapeutics
To add a bio or update company history, please click update information.
News from TRIMTECH Therapeutics
TRIMTECH Therapeutics
23 Jun 2026
TRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases
TRIMTECH Therapeutics is a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases. Its TRIMTAC and TRIMGLUE platforms are designed to selectively degrade toxic protein aggregates and oligomers whilst leaving functional monomeric forms of those proteins intact to support healthy cellular function.
TRIMTECH Therapeutics
5 Mar 2025
TRIMTECH raises £24m seed led by Cambridge Innovation Capital and SV Health Investors to advance neurodegenerative treatments
TRIMTECH Therapeutics develops targeted protein degradation medicines that selectively remove harmful protein aggregates, focusing on neurodegenerative and inflammatory diseases with limited existing treatment options.
TRIMTECH Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £35m
- trimtechtherapeutics.com
- Update Information
More venture news
- 26 Oct 2026
adsilicoadsilico unlocks a £10m Series A round led by PXN Ventures for virtual testing of implantable medical devices
Series ALife Sciences - 26 Oct 2026
imphatecimphatec raises a £1.5m seed round led by SynBioVen to develop customisable-dose implants for chronic conditions
SeedLife Sciences - 15 Oct 2026
OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences
